Rosetta Genomics has appointed Kenneth Berlin as president and CEO. Berlin will also serve on the company’s board of directors. Since 2007 Berlin has been worldwide general manager at cellular and molecular cancer diagnostics company Veridex.
Nanosphere said last week that Chief Technology Officer and Vice President of R&D William Cork has resigned from his positions to pursue other opportunities, and that his duties will be reassigned.
WaferGen Biosystems has appointed Christopher Sears to its scientific advisory board. Sears is chief scientific officer at Ambergen, and he has worked as an academic oncologist at Children’s Hospital Boston, The Broad Institute, Harvard Medical School, and Dana Farber Cancer Institute. Sears also has been a scientific adviser to Genzyme Genetics, Myriad Genetics, and Invitrogen.
Sequenom has appointed Paul Maier to begin serving as its interim chief financial officer. He has worked as senior vice president and CFO of Ligand Pharmaceuticals, where he helped build the company from its venture stage through raising more than $1 billion in equity and debt financings. He also worked at ICN Pharmaceuticals for six years in various management and finance positions.